Amgen's been working on combining their drug with checkpoint inhibitors for non-small cell lung cancer, and yeah, the data does look promising in trials. The combination appears to extend survival better than what we've seen with some existing approaches, which is genuinely meaningful for patients who don't have a lot of great options. That said, trial results and real-world outcomes don't always line up perfectly - what works in a controlled study with specific patient populations can behave differently once it's out there treating everyone.
Whether this counts as a "breakthrough" depends on your baseline. If you're comparing it to nothing, absolutely. If you're comparing it to existing immunotherapy combinations that some folks are already using, it's more of an incremental improvement in the right direction. The honest take is that lung cancer treatment has been moving forward steadily over the past decade or so, with multiple drugs showing benefit in different patient subgroups. This looks like it fits into that pattern of progress rather than being a total game-changer out of nowhere.
People should definitely be aware that it exists and talk to their doctors about whether it might apply to their specific situation, but managing expectations matters too. Regulatory approval and actual availability can take time, and insurance coverage isn't always straightforward even after approval. If someone's dealing with lung cancer or has a family member who is, this is worth bringing up at their next appointment - just without assuming it's necessarily the answer for their particular case.